263 related articles for article (PubMed ID: 19136028)
1. A pragmatic approach to biochemical systems theory applied to an alpha-synuclein-based model of Parkinson's disease.
Sass MB; Lorenz AN; Green RL; Coleman RA
J Neurosci Methods; 2009 Apr; 178(2):366-77. PubMed ID: 19136028
[TBL] [Abstract][Full Text] [Related]
2. The role of ubiquitin linkages on alpha-synuclein induced-toxicity in a Drosophila model of Parkinson's disease.
Lee FK; Wong AK; Lee YW; Wan OW; Chan HY; Chung KK
J Neurochem; 2009 Jul; 110(1):208-19. PubMed ID: 19457126
[TBL] [Abstract][Full Text] [Related]
3. Intragastric proteasome inhibition induces alpha-synuclein-immunopositive aggregations in neurons in the dorsal motor nucleus of the vagus in rats.
Miwa H; Kubo T; Suzuki A; Kondo T
Neurosci Lett; 2006 Jun; 401(1-2):146-9. PubMed ID: 16600504
[TBL] [Abstract][Full Text] [Related]
4. Proteasomal inhibition hypersensitizes differentiated neuroblastoma cells to oxidative damage.
Lev N; Melamed E; Offen D
Neurosci Lett; 2006 May; 399(1-2):27-32. PubMed ID: 16584840
[TBL] [Abstract][Full Text] [Related]
5. A molecular pathway of neurodegeneration linking alpha-synuclein to ApoE and Abeta peptides.
Gallardo G; Schlüter OM; Südhof TC
Nat Neurosci; 2008 Mar; 11(3):301-8. PubMed ID: 18297066
[TBL] [Abstract][Full Text] [Related]
6. Proteomic analysis of dopamine and α-synuclein interplay in a cellular model of Parkinson's disease pathogenesis.
Alberio T; Bossi AM; Milli A; Parma E; Gariboldi MB; Tosi G; Lopiano L; Fasano M
FEBS J; 2010 Dec; 277(23):4909-19. PubMed ID: 20977677
[TBL] [Abstract][Full Text] [Related]
7. Alpha-synuclein nitration and autophagy response are induced in peripheral blood cells from patients with Parkinson disease.
Prigione A; Piazza F; Brighina L; Begni B; Galbussera A; Difrancesco JC; Andreoni S; Piolti R; Ferrarese C
Neurosci Lett; 2010 Jun; 477(1):6-10. PubMed ID: 20399833
[TBL] [Abstract][Full Text] [Related]
8. Aggregation-defective alpha-synuclein mutants inhibit the fibrillation of Parkinson's disease-linked alpha-synuclein variants.
Koo HJ; Choi MY; Im H
Biochem Biophys Res Commun; 2009 Aug; 386(1):165-9. PubMed ID: 19501571
[TBL] [Abstract][Full Text] [Related]
9. Controlling the mass action of alpha-synuclein in Parkinson's disease.
Kim C; Lee SJ
J Neurochem; 2008 Oct; 107(2):303-16. PubMed ID: 18691382
[TBL] [Abstract][Full Text] [Related]
10. Dynamic modeling of α-synuclein aggregation in dopaminergic neuronal system indicates points of neuroprotective intervention: experimental validation with implications for Parkinson's therapy.
Sultana Z; Paleologou KE; Al-Mansoori KM; Ardah MT; Singh N; Usmani S; Jiao H; Martin FL; Bharath MM; Vali S; El-Agnaf OM
Neuroscience; 2011 Dec; 199():303-17. PubMed ID: 22056602
[TBL] [Abstract][Full Text] [Related]
11. Molecular pathogenesis of Parkinson's disease.
Gandhi S; Wood NW
Hum Mol Genet; 2005 Sep; 14(18):2749-55. PubMed ID: 16126732
[TBL] [Abstract][Full Text] [Related]
12. A cell-based model of alpha-synucleinopathy for screening compounds with therapeutic potential of Parkinson's disease.
Zhao DL; Zou LB; Zhou LF; Zhu P; Zhu HB
Acta Pharmacol Sin; 2007 May; 28(5):616-26. PubMed ID: 17439717
[TBL] [Abstract][Full Text] [Related]
13. Heat shock proteins reduce alpha-synuclein aggregation induced by MPP+ in SK-N-SH cells.
Fan GH; Zhou HY; Yang H; Chen SD
FEBS Lett; 2006 May; 580(13):3091-8. PubMed ID: 16678164
[TBL] [Abstract][Full Text] [Related]
14. Plasma alpha-synuclein in patients with Parkinson's disease with and without treatment.
Duran R; Barrero FJ; Morales B; Luna JD; Ramirez M; Vives F
Mov Disord; 2010 Mar; 25(4):489-93. PubMed ID: 20063406
[TBL] [Abstract][Full Text] [Related]
15. Mathematical approach to understand the kinetics of alpha-synuclein aggregation: relevance to Parkinson's disease.
Bharathi P; Nagabhushan P; Rao KS
Comput Biol Med; 2008 Oct; 38(10):1084-93. PubMed ID: 18823621
[TBL] [Abstract][Full Text] [Related]
16. Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions.
Chu Y; Dodiya H; Aebischer P; Olanow CW; Kordower JH
Neurobiol Dis; 2009 Sep; 35(3):385-98. PubMed ID: 19505575
[TBL] [Abstract][Full Text] [Related]
17. Toxic effects of dopamine metabolism in Parkinson's disease.
Hattoria N; Wanga M; Taka H; Fujimura T; Yoritaka A; Kubo S; Mochizuki H
Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S35-8. PubMed ID: 19131041
[TBL] [Abstract][Full Text] [Related]
18. alpha-Synuclein, oxidative stress and apoptosis from the perspective of a yeast model of Parkinson's disease.
Witt SN; Flower TR
FEMS Yeast Res; 2006 Dec; 6(8):1107-16. PubMed ID: 17156009
[TBL] [Abstract][Full Text] [Related]
19. Anti-aggregation and fibril-destabilizing effects of sex hormones on alpha-synuclein fibrils in vitro.
Hirohata M; Ono K; Morinaga A; Ikeda T; Yamada M
Exp Neurol; 2009 Jun; 217(2):434-9. PubMed ID: 19289119
[TBL] [Abstract][Full Text] [Related]
20. Convergent roles of alpha-synuclein, DA metabolism, and the ubiquitin-proteasome system in nigrostriatal toxicity.
Fornai F; Lazzeri G; Bandettini Di Poggio A; Soldani P; De Blasi A; Nicoletti F; Ruggieri S; Paparelli A
Ann N Y Acad Sci; 2006 Aug; 1074():84-9. PubMed ID: 17105905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
